Holmes M, Mahar A, Lum T, et al. - A retrospective study was performed to evaluate the real-world prevalence of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) and any correlations with clinicopathological features. Researchers examined 425 NSCLC cases at a Sydney metropolitan hospital that had PD-L1 IHC (SP263 clone) expression calculated as part of routine diagnostic assessment during a 30-month period. The results revealed that ongoing observation and comparison of PD-L1 expression rates is an important practice for ensuring its validity as a predictive biomarker. The outcomes of this research align with and contribute to the growing field of published real-world PD-L1 prevalence rates in NSCLC.